Method for treating Parkinson's disease through photostimulation and device used in method

Abstract

The present invention provides a method of treating Parkinson's disease by photostimulation in which light of a specific wavelength, such as purple light, is irradiated at a specific flicker frequency; the invention also relates to a device used in the method. The present invention improves or suppresses at least one symptom selected from the following symptom group by irradiating a living body with light of a specific wavelength, such as purple light, the composition is used for treating and / or preventing Parkinson's disease: cognitive / memory impairment, working memory impairment, depression, anxiety, cold desert, psychological symptoms (hallusion, visual hallusion and auditory hallusion), impulse control impairment, upright hypotension, dysuria, sexual dysfunction, digestive organ dysfunction (saliva, swallowing, nausea, constipation), sleep disorder, pain, weight loss, anomalies, and the like. Fatigue and sweating.

Description

Technical Field

[0001] The present invention relates to a method for treating diseases through light stimulation and a device used therefor. More specifically, the present invention relates to a method for treating Parkinson's disease through light stimulation (irradiating light of a specific wavelength such as purple light at a specific flickering frequency) and a device used therefor. Background Art

[0002] In recent years, the effects of light on the human body have been studied from many perspectives and reported based on new findings. For example, it has been reported that sunbathing can improve circadian rhythms (non-patent document 1); light irradiated from displays such as liquid crystal displays (where LED (light emitting diode) lighting and LEDs are used as backlights) has a significant impact on the body and mind (non-patent document 2); ultraviolet light prevents myopia and inhibits the development of myopia (patent document 1). In particular, in recent years, the inventors of the present invention have submitted interesting reports on the effects of ultraviolet light on the eyes. For example, in patent document 1 and non-patent document 3, it is proposed that light of a specific wavelength is effective in preventing myopia and inhibiting myopia, which is highly anticipated given that the number of myopic people around the world has continued to rise in recent years.

[0003] Furthermore, research and development of various treatment technologies are also active, and research and development of treatment technologies that reduce the burden on the body, particularly by not using drugs or reducing the use of drugs, has been carried out.

[0004] For example, in Patent Document 2 and Non-Patent Document 4, it is reported that in a study using mice with Alzheimer's disease, when the regulation of gamma wave oscillations in the brain is restored, β-amyloid protein accumulated in the brain is cleared.

[0005] Citation List

[0006] Non-patent literature

[0007] Non-patent literature 1: Anti-aging medicine, Megumi Hatori and Kazuo Tsubota, Japanese Society of Anti-aging Medicine Magazine, Vol. 11, No. 3, 065(385)-072(392), (2015)

[0008] Non-patent document 2: “Blue Light Hazards”, Kazuo Tsubota, published by Shueisha on November 20, 2013

[0009] Non-patent literature 3: Hidemasa Torii et al., EBioMedicine, "DOI:

[0010] http: / / dx.doi.org / 10.1016 / j.ebiom.2016.12.007”

[0011] Non-patent document 4: Nature, Vol. 540, No. 8, December 2016, pp. 231-235

[0012] Patent Literature

[0013] Patent document 1: WO2015 / 186723A1

[0014] Patent Document 2: US2017 / 0304584A1 Summary of the invention

[0015] Problems to be solved by the present invention

[0016] Parkinson's disease (PD) is a neurodegenerative disease with the second largest number of patients after Alzheimer's disease, and is characterized by motor symptoms such as tremor and non-motor symptoms such as psychological symptoms. From the perspective of molecular and cell biology, the loss of dopaminergic neurons in the substantia nigra and the formation of intracellular Lewy bodies made of α-synuclein and ubiquitin 1 have been recognized. In addition, in Parkinson's disease model mice (Atg7 gene knockout mice), deposition of p62 protein was observed. p62 is a protein with ubiquitin binding domains and LC3 binding domains, and is known to have the function of transporting ubiquitinated proteins to autophagosomes. Although the research and development of treatment methods for Parkinson's disease has been actively promoted, there is no fundamental treatment for Parkinson's disease at this stage, and supportive measures to relieve symptoms are mainly used. The basis of treatment is drug therapy and supplementary treatment of reduced dopamine. As drugs, dopamine precursors (such as levodopa) and dopamine agonists (such as ropinirole) have been used. However, one side effect of dopamine replacement therapy is visual hallucinations. To improve visual hallucinations, dopamine replacement therapy must be reduced and antipsychotic drugs must be used, and worsening of motor symptoms has become a problem.

[0017] The inventors of the present invention have found that irradiating light of a specific wavelength, in particular violet light (light in the range of 360nm to 400nm) with a flickering frequency improves symptoms caused by Parkinson's disease or its treatment. One object of the present invention is to provide a method for treating and / or preventing Parkinson's disease by irradiating light of a specific wavelength (such as violet light) continuously or with a specific flickering frequency, as well as an apparatus and a computer program for this method.

[0018] The present invention includes providing a method for treating and / or preventing motor symptoms, non-motor symptoms and / or other elements of a Parkinson's disease patient caused by Parkinson's disease or its treatment, as well as a device and a computer program for treating and / or preventing the same. Here, the symptoms caused by Parkinson's disease treatment can be symptoms caused by dopamine supplementation therapy.

[0019] Means of solving the problem

[0020] The present disclosure provides a method for treating and / or preventing Parkinson's disease by irradiating a subject with light of a specific wavelength. More preferably, the present invention provides a method for treating and / or preventing motor symptoms, non-motor symptoms and / or other aspects of Parkinson's disease by irradiating a subject with violet light (VL) continuously or at a specific flickering frequency.

[0021] In addition, according to one aspect, the present disclosure provides a method for treating and / or preventing Parkinson's disease by controlling a light irradiation device to irradiate a subject with light of a specific wavelength. In some embodiments, the light irradiation device includes a light source and a controller, the light source irradiates a specific wavelength of light to a living body continuously or at a specific flickering frequency, and the controller controls the flickering frequency of the light source. The method includes: treating and / or preventing a subject's motor symptoms, non-motor symptoms, and other aspects by irradiating a subject with light of a specific wavelength through a light irradiation device.

[0022] According to another aspect, the present disclosure relates to a method for treating and / or preventing motor symptoms, non-motor symptoms and / or other aspects of a subject in need of treatment and / or prevention, the method comprising irradiating light of a specific wavelength to the subject. The subject to which the method according to the present disclosure is applied may be a patient suffering from Parkinson's disease.

[0023] According to yet another aspect, the present disclosure provides a method for treating and / or preventing cognitive memory impairment, working memory impairment, irritability, anxiety, apathy, and psychological symptoms (hallucinations, visual hallucinations, and auditory hallucinations) associated with Parkinson's disease.

[0024] In other words, the present disclosure is as follows.

[0025] [Project 1]

[0026] A method for treating and / or preventing Parkinson's disease comprises irradiating a subject with light of a specific wavelength by using a light irradiation device.

[0027] [Project 2]

[0028] The method for treating and / or preventing Parkinson's disease according to Item 1 is characterized by treating and / or preventing motor symptoms and / or non-motor symptoms of Parkinson's disease.

[0029] [Item 3]

[0030] The method according to item 2, wherein the motor symptom is at least one symptom selected from the following symptom group: difficulty in speaking, drooling (excessive drooling), difficulty chewing, difficulty swallowing, difficulty in eating movements, difficulty changing clothes, difficulty maintaining personal hygiene, difficulty writing, reduced hobbies and recreational activities, difficulty turning over, tremor, difficulty getting up from bed, chair and wheelchair, difficulty walking, loss of balance, freezing of gait (FOG), walking stiffness, difficulty in speech, loss of facial expression, rigidity, finger tapping, hand movement disorder, hand pronation and supination movement disorder, toe tapping, lower limb agility disorder, postural stability disorder, difficulty maintaining posture, general spontaneity of movement (bradykinesia), postural tremor of the hand, kinetic tremor of the hand, resting tremor amplitude and restless legs syndrome.

[0031] [Item 4]

[0032] A method according to one of items 2 and 3, wherein the non-motor symptom is at least one symptom selected from the following symptom group: cognitive impairment, attention dysfunction, cognitive memory impairment, working memory impairment, depression, anxiety, sense of urgency, apathy, psychological symptoms (hallucinations, visual hallucinations, delusions and auditory hallucinations), dopamine disorder syndrome, impulse control disorder, orthostatic hypotension, postural hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain and other sensory abnormalities (smell abnormalities and visual abnormalities), weight changes, fatigue, sweating and syncope.

[0033] [Item 5]

[0034] The method according to item 4, wherein at least one symptom selected from the following symptom group is caused by Parkinson's disease: cognitive impairment, attention dysfunction, cognitive memory impairment, working memory impairment, depression, anxiety, sense of urgency, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), dopamine disorder syndrome, impulse control disorder, orthostatic hypotension, postural hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain and other sensory abnormalities (smell abnormalities and visual abnormalities), weight changes, fatigue, sweating and syncope.

[0035] [Item 6]

[0036] The method according to any one of items 1 to 5, which is a method for treating and / or preventing Parkinson's disease, characterized in that dyskinesia is treated and / or prevented.

[0037] [Item 7]

[0038] The method according to any one of items 1 to 6, characterized in that Parkinson's disease is classified into one of grades I, II, III, IV and V according to the Hoehn & Yahr severity grade classification.

[0039] [Item 8]

[0040] The method according to any one of items 1 to 7 is characterized in that light of a specific wavelength is irradiated to the subject continuously or at a specific flashing frequency.

[0041] [Item 9]

[0042] The method according to any one of items 1 to 8, characterized in that the subject is currently taking or has taken at least one agent selected from the group consisting of levodopa, phenylalanine, tyrosine, bromocriptine mesylate, pergolide mesylate, cabergoline, talipexole hydrochloride, pramipexole hydrochloride, ropinirole hydrochloride, rotigotine, apomorphine hydrochloride hydrate, trihexyphenidyl hydrochloride, hydrochloride, biperiden, selegiline, safinamide, rasagiline, entacapone, opicapone, droxidopa, istradefylline, quetiapine, zonisamide, and amantadine.

[0043] [Item 10]

[0044] The method according to any one of items 1 to 9, wherein the light is violet light.

[0045] [Item 11]

[0046] A method according to any one of items 1 to 10, wherein the specific wavelength comprises a wavelength in the range of 360 nm to 400 nm.

[0047] [Item 12]

[0048] A method according to any one of items 1 to 11, wherein the specific wavelength comprises a wavelength of about 380 nm.

[0049] [Item 13]

[0050] The method according to any one of items 1 to 12, characterized in that the light is one of a light that irradiates continuously or a light that flashes at a specific flashing frequency.

[0051] [Item 14]

[0052] A method according to item 13, wherein the flickering frequency is in the range of 30 Hz to 70 Hz.

[0053] [Item 15]

[0054] A method according to one of items 13 and 14, wherein the flickering frequency is in the range of 35 Hz to 60 Hz.

[0055] [Item 16]

[0056] A method according to any one of items 13 to 15, wherein the flashing frequency is 40 Hz.

[0057] [Item 17]

[0058] The method according to any one of items 1 to 16, characterized in that the light is irradiated during daytime.

[0059] [Item 18]

[0060] The method according to any one of items 1 to 17, characterized in that the light is irradiated for 10 seconds or longer as the total time of light irradiation.

[0061] [Item 19]

[0062] A method according to any one of items 1 to 18, wherein the light is irradiated so that the irradiance of the light incident on the eye is between 0.5 μW / cm 2 Up to 1000μW / cm 2 within the range.

[0063] [Item 20]

[0064] The method according to any one of items 1 to 19, characterized in that the light is irradiated for 5 minutes or more as the total light irradiation time.

[0065] [Item 21]

[0066] A method according to any one of items 1 to 20, wherein the light irradiation device is glasses with a light source or a glasses frame with a light source, a desktop light source, a light source installed in a mobile terminal, a light source installed near or in front of the face, a portable light source, indoor lighting and a desk lamp.

[0067] [Item 22]

[0068] A method according to any one of items 1 to 21, wherein the subject is a human.

[0069] [Item 23]

[0070] A device for treating and / or preventing Parkinson's disease by irradiating a subject with light of a specific wavelength continuously or at a specific flickering frequency, characterized in that the device comprises a light source that irradiates light of a specific wavelength continuously or at a specific flickering frequency.

[0071] [Item 24]

[0072] The device according to Item 23 is characterized in that it also includes a controller for controlling the emission of light, wherein the light induces specific brain waves that are the same, substantially the same, or different from the light irradiation state in the subject irradiated with the light.

[0073] [Item 25]

[0074] The device according to item 24, wherein the controller performs control by changing irradiation conditions such as a flashing frequency of light of a specific wavelength, irradiance, irradiation time, irradiation start time, and irradiation end time by transmitting and receiving with a separate controller such as a portable terminal.

[0075] [Item 26]

[0076] The device according to item 25 is characterized in that it also includes a driving circuit for driving the light source.

[0077] [Item 27]

[0078] The device according to item 26,

[0079] The driving circuit includes at least one processor and at least one memory for storing commands executable by the processor, and

[0080] The processor is communicatively connected to the light source and the memory.

[0081] [Item 28]

[0082] The device according to any one of items 23 to 27, wherein the device for treating and / or preventing Parkinson's disease is characterized by treating and / or preventing motor symptoms and / or non-motor symptoms of Parkinson's disease.

[0083] [Item 29]

[0084] The device according to item 28, wherein the motor symptom is at least one symptom selected from the following symptom group: difficulty speaking, drooling (excessive drooling), difficulty chewing, difficulty swallowing, difficulty eating movements, difficulty changing clothes, difficulty maintaining personal hygiene, difficulty writing, reduced hobbies and recreational activities, difficulty turning over, tremor, difficulty getting up from bed, chair and wheelchair, difficulty walking, loss of balance, freezing of gait (FOG), walking stiffness, speech difficulties, loss of facial expression, rigidity, finger tapping, hand movement disorder, hand pronation and supination movement disorder, toe tapping, lower limb agility disorder, postural stability disorder, difficulty maintaining posture, global spontaneity of movement (bradykinesia), hand postural tremor, hand kinesiology tremor, resting tremor amplitude, resting tremor and restless legs syndrome.

[0085] [Item 30]

[0086] A device according to one of items 28 and 29, wherein the non-motor symptom is at least one symptom selected from the following symptom group: cognitive impairment, attention dysfunction, cognitive memory impairment, working memory impairment, depression, anxiety, sense of urgency, apathy, psychological symptoms (hallucinations, visual hallucinations, delusions and auditory hallucinations), dopamine disorder syndrome, impulse control disorder, orthostatic hypotension, postural hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain and other sensory abnormalities (smell abnormalities and visual abnormalities), weight changes, fatigue, sweating and syncope.

[0087] [Item 31]

[0088] The device according to item 30, wherein at least one symptom selected from the following symptom group is caused by Parkinson's disease: cognitive impairment, attention dysfunction, cognitive memory impairment, working memory impairment, depression, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations, delusions and auditory hallucinations), dopamine disorder syndrome, impulse control disorder, orthostatic hypotension, postural hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain and other sensory abnormalities (smell abnormalities and visual abnormalities), weight changes, fatigue, sweating and syncope.

[0089] [Item 32]

[0090] The device according to any one of items 23 to 31, wherein the device for treating and / or preventing Parkinson's disease is characterized by treating and / or preventing dyskinesia.

[0091] [Item 33]

[0092] The device according to any one of items 23 to 32 is characterized in that Parkinson's disease is classified into one of Grade I, Grade II, Grade III, Grade IV and Grade V according to the Hoehn & Yahr severity level classification.

[0093] [Item 34]

[0094] The device according to any one of items 23 to 33, characterized in that the subject is currently administering or has administered at least one agent selected from the group consisting of: levodopa, phenylalanine, tyrosine, bromocriptine mesylate, pergolide mesylate, cabergoline, talipexole hydrochloride, pramipexole hydrochloride, ropinirole hydrochloride, rotigotine, apomorphine hydrochloride hydrate, trihexyphenidyl hydrochloride, biperiden, selegiline, safinamide, rasagiline, entacapone, opicapone, droxidopa, istradefylline, quetiapine, zonisamide and amantadine.

[0095] [Item 35]

[0096] A device according to any of items 23 to 34, wherein the light is violet light.

[0097] [Item 36]

[0098] An apparatus according to any of items 23 to 35, wherein the specific wavelength comprises a wavelength in the range of 360nm to 400nm.

[0099] [Item 37]

[0100] A device according to any of items 23 to 36, wherein the specific wavelength comprises a wavelength of approximately 380 nm.

[0101] [Item 38]

[0102] A device according to any of items 23 to 37, wherein the flickering frequency is in the range of 30 Hz to 70 Hz.

[0103] [Item 39]

[0104] A device according to any of items 23 to 38, wherein the flickering frequency is in the range of 35 Hz to 60 Hz.

[0105] [Item 40]

[0106] A device according to any one of items 23 to 39, wherein the flashing frequency is 40 Hz.

[0107] [Item 41]

[0108] The device according to any one of items 23 to 40 is characterized in that the light is irradiated during daytime.

[0109] [Item 42]

[0110] The device according to any one of items 23 to 41, characterized in that the light is irradiated for 10 seconds or longer as the total time of light irradiation.

[0111] [Item 43]

[0112] A device according to any one of items 23 to 42, wherein the light is irradiated so that the irradiance of the light incident on the eye is between 0.5 μW / cm 2 Up to 1000μW / cm 2 within the range.

[0113] [Item 44]

[0114] The device according to any one of items 23 to 43, characterized in that the light is irradiated for 5 minutes or more as the total time of light irradiation.

[0115] [Item 45]

[0116] A device according to any one of items 23 to 44, wherein the light irradiation device is glasses with a light source or a glasses frame with a light source, a desktop light source, a light source installed in a mobile terminal, a light source installed near or in front of the face, a portable light source, indoor lighting and a desk lamp.

[0117] [Item 46]

[0118] A device according to any one of items 23 to 45, wherein light, sound, vibration, magnetic field and electric field of different wavelengths are applied together with the light irradiation of a specific wavelength.

[0119] [Item 47]

[0120] A computer-readable medium, which is a non-transitory computer-readable medium storing commands and capable of causing the device according to any one of items 23 to 46 (including a light source for irradiating a biological body with light of a specific wavelength continuously or at a specific flashing frequency, and a controller for controlling the flashing frequency of the light source) to perform the following steps when a processor executes the commands:

[0121] The step of operating the device so that the controller controls the flickering frequency of the light source to 0 Hz or a frequency in the range of 30 Hz to 75 Hz, and

[0122] A step of operating the device so that the light source irradiates light with a wavelength in the range of 360 nm to 400 nm toward the biological body.

[0123] [Item 48]

[0124] An apparatus for treating and / or preventing Parkinson's disease by light stimulation, comprising glass, eyeglass lenses or contact lenses that allow violet light to pass through.

[0125] Specific examples of Parkinson's disease motor symptoms treated and / or prevented by the present invention include difficulty speaking, drooling (excessive drooling), difficulty chewing, difficulty swallowing, difficulty eating movements, difficulty changing clothes, difficulty maintaining personal hygiene, difficulty writing, reduced hobbies and recreational activities, difficulty turning over, tremor, difficulty getting up from a bed, chair, and wheelchair, difficulty walking, loss of balance, freezing of gait (FOG), walking stiffness, speech difficulties, loss of facial expression, rigidity, finger tapping, hand movement disorders, hand pronation and supination movement disorders, toe tapping, lower limb agility disorders, postural stability disorders, difficulty maintaining posture, global spontaneity of movement (bradykinesia), hand postural tremor, hand kinetic tremor, resting tremor amplitude, resting tremor, and restless legs syndrome.

[0126] Specific examples of non-motor symptoms of Parkinson's disease treated and / or prevented by the present invention include cognitive impairment, attention dysfunction, cognitive memory impairment, working memory impairment, depression, anxiety, urgency, apathy, psychological symptoms (hallucinations, visual hallucinations, delusions and auditory hallucinations), dopamine dysregulation syndrome, impulse control disorders, orthostatic hypotension, postural hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain and other sensory abnormalities (smell abnormalities and visual abnormalities), weight changes, fatigue, sweating and syncope.

[0127] More preferred examples of non-motor symptoms of Parkinson's disease to be treated and / or prevented by the present invention include cognitive memory impairment, working memory impairment, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating.

[0128] Even more preferred examples of non-motor symptoms of Parkinson's disease to be treated and / or prevented by the present invention include visual hallucinations, auditory hallucinations, sleep disorders and cognitive memory disorders.

[0129] Specific examples of symptoms of Parkinson's disease that are treated and / or prevented by the present invention include dyskinesias in patients with Parkinson's disease, or in other words, the timing of dyskinesias, the effects of dyskinesias on function, the time spent in the off-state, the effects of symptom fluctuations on function, the complexity of motor symptom fluctuations, and dystonia in the off-state accompanied by pain.

[0130] In the context of the present disclosure, patients suffering from Parkinson's disease may include patients classified as any of Grade I, Grade II, Grade III, Grade IV, and Grade V according to the Hoehn & Yahr severity scale.

[0131] When applying the methods described in the present disclosure, the subject may be a patient who is currently taking or has been taken at least one anti-Parkinson's drug.

[0132] Examples of anti-Parkinson's drugs include at least one or more agents selected from the group consisting of: dopamine precursors, dopamine agonists, anticholinergic agents, monoamine oxidase B inhibitors (MAO-B inhibitors), COMT inhibitors (catechol-O-methyltransferase inhibitors), norepinephrine precursors, adenosine A2A antagonists, antipsychotic agents, zonisamide and / or amantadine.

[0133] Specific examples of dopamine precursors include phenylalanine, tyrosine, and levodopa (L-dopa).

[0134] Specific examples of the dopamine agonist include bromocriptine mesylate, pergolide mesylate, cabergoline, talipexole hydrochloride, pramipexole hydrochloride, ropinirole hydrochloride, rotigotine, and apomorphine hydrochloride hydrate.

[0135] Specific examples of anticholinergic agents include trihexyphenidyl hydrochloride and biperiden.

[0136] Specific examples of monoamine oxidase B inhibitors (MAOB inhibitors) include selegiline, safinamide, and rasagiline.

[0137] Specific examples of COMT inhibitors include entacapone and opicapone.

[0138] Specific examples of norepinephrine precursors include droxidopa.

[0139] Specific examples of adenosine A2A antagonists include istradefylline.

[0140] Specific examples of antipsychotic agents include quetiapine.

[0141] In addition, according to one aspect, the present disclosure relates to a method for treating and / or preventing Parkinson's disease in a subject in need of treatment and / or prevention, the method comprising inhibiting or improving the deposition of alpha-synuclein and / or p62 protein in the brain by irradiating light of a specific wavelength to the subject. In some embodiments, the present disclosure relates to a method comprising irradiating light of a specific wavelength to the subject, and inhibiting or improving the deposition of alpha-synuclein and / or p62 protein in the brain of a patient with Parkinson's disease.

[0142] In addition, according to one aspect, the present disclosure relates to a method for accelerating the proliferation and / or differentiation of oligodendrocytes in a patient with Parkinson's disease in need of treatment and / or prevention, the method comprising irradiating light of a specific wavelength to the patient. In addition, in some embodiments, the present disclosure relates to a method for treating and / or preventing Parkinson's disease in a subject in need of treatment and / or prevention, the method comprising irradiating light of a specific wavelength to the subject, and thereby accelerating the proliferation and / or differentiation of oligodendrocytes in the subject, thereby treating and / or preventing Parkinson's disease in the subject. It is known that in Parkinson's disease, the number of oligodendrocytes and differentiated myelin sheaths, which are glial cells, is reduced, and therefore accelerating the proliferation and differentiation of oligodendrocytes is considered to be of great significance for the treatment and / or prevention of Parkinson's disease.

[0143] In some embodiments, the light used is violet light.

[0144] In some embodiments, the specific wavelengths used include wavelengths within the range of 360 nm to 400 nm, and particularly include a wavelength of about 380 nm.

[0145] In some embodiments, the flickering frequency used is 0 Hz or a frequency in the range of 30 Hz to 70 Hz, in particular 0 Hz or a frequency in the range of 35 Hz to 60 Hz, more particularly, for example 0 Hz or about 40 Hz.

[0146] In some embodiments, the irradiation conditions further include the irradiation time of the light source.

[0147] In some embodiments, the light source can be glasses with a light source or a glasses frame with a light source, a desktop light source, a light source mounted on a mobile terminal, a light source mounted near or in front of the face, a portable light source, indoor lighting, and a desk lamp.

[0148] Preferred examples of light sources include glasses with a light source or a glasses frame with a light source, a desktop light source, a light source mounted on a mobile terminal, a light source mounted near or in front of the face, a portable light source, and a desk lamp.

[0149] More preferred examples of light sources include glasses with a light source or a glasses frame with a light source, a desktop light source, a light source mounted on a mobile terminal, or a light source mounted near or in front of the face.

[0150] Even more preferred examples of light sources include glasses with a light source or glasses frames with a light source or a desktop light source.

[0151] Most preferred examples of the light source include glasses with a light source or glasses frames with a light source.

[0152] In some embodiments, the subject to which the present disclosure is applied is a human.

[0153] According to one aspect, the present disclosure relates to a device for treating and / or preventing Parkinson's disease through light stimulation, the device comprising at least one light source and a driving circuit for driving the light source, the light emitted by the light source is light of a specific wavelength, which produces the effect of treating and / or preventing Parkinson's disease by irradiating a biological body.

[0154] In addition, according to one aspect, the present disclosure relates to a device for treating and / or preventing motor symptoms, non-motor symptoms and / or other symptoms by irradiating light to a biological body, the device comprising at least one light source for emitting light and a driving circuit for driving the light source.

[0155] In some embodiments, the driving circuit in the device described in the present disclosure includes at least one processor connected to the light source and at least one memory, and at least one memory for storing commands executable by the processor.

[0156] According to one aspect, the present disclosure relates to a method for operating the device described in the present disclosure, which includes a light source that irradiates light of a specific wavelength to a biological body continuously or at a specific flickering frequency and a controller that controls the flickering frequency of the light source, the method including: a step of controlling the flickering frequency of the light source to 0 Hz or a frequency in the range of 30 Hz to 75 Hz by the controller; and a step of irradiating light with a wavelength in the range of 360 nm to 400 nm by the light source.

[0157] According to one aspect, the present disclosure relates to a computer program that enables a device to execute the operating method described in the present disclosure, the device including a light source that irradiates light of a specific wavelength to a biological body continuously or at a specific flickering frequency and a controller that controls the flickering frequency of the light source.

[0158] In the method and device according to the present disclosure, the light is, for example, violet light. According to the present invention, since violet light can be irradiated to an organism, it can affect the organism without causing the flickering or dazzling sensation caused by white light. Violet light refers to light with a wavelength in the range of 360nm to 400nm, which has a lower relative visibility than white light and is a wavelength region that does not cause discomfort or hardly causes any discomfort to an organism (especially humans).

[0159] In some embodiments of the present disclosure, light having a wavelength in the range of 350nm to 400nm can be used, for example, light having a wavelength of any one of 350nm, 360nm, 370nm, 380nm, 390nm or 400nm, or light of any wavelength contained in the range specified by any of the above wavelengths (for example, in the range of 370nm to 390nm) can be used. In some embodiments of the present disclosure, the wavelength includes a wavelength of about 380nm. The term "about" as used in this specification refers to any value within a range of no more than ±5% of the value modified by the term.

[0160] In the method and apparatus described in the present disclosure, the irradiation condition of light is continuous irradiation (in other words, 0 Hz) or irradiation with a flickering frequency in the range of more than 0 Hz to 150 Hz.

[0161] In some embodiments of the present disclosure, continuous irradiation light (0 Hz) or light with a flickering frequency in the range of 30 Hz to 75 Hz, such as light with a flickering frequency of 30 Hz, 35 Hz, 40 Hz, 45 Hz, 50 Hz, 55 Hz, 60 Hz, 65 Hz, 70 Hz or 75 Hz, or light with any flickering frequency within the range specified by any of the above flickering frequencies (e.g., within the range of 35 Hz to 45 Hz) can be used. In some embodiments of the present disclosure, the flickering frequency is about 40 Hz.

[0162] In the method and apparatus according to the present disclosure, light can be irradiated so that the irradiance of the light incident on the eye is, for example, at 0.5 μW / cm 2 Up to 1000μW / cm 2 In the range of 0.1μW / cm 2 (0.001W / m 2 ) to 5000μW / cm 2 (50W / m 2 ). According to some embodiments, it is believed that by irradiating light (such as violet light) within the above irradiance range, an effect on the central nervous system can be produced. Generally speaking, even if violet light is a weak light (low intensity light) of a small amount (light with weak optical sensitivity), it has been confirmed that it can induce characteristic phenomena.

[0163] In the method and device according to the present disclosure, the controller of the device can perform control by transmitting and receiving with an independent controller such as a portable terminal, by changing the irradiation conditions such as the irradiation state of light (including continuous irradiation or irradiation with a flashing frequency), irradiance, irradiation time, irradiation start time, irradiation end time, constant irradiation or flashing frequency. According to some embodiments, since the above-mentioned various irradiation conditions are independently controlled, the desired effect can be achieved by arbitrarily setting appropriate irradiation conditions to produce the effect of treating and / or preventing at least one symptom selected from the following: motor symptoms and non-motor symptom groups, or in other words, cognitive memory disorders, working memory disorders, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating.

[0164] In the method and apparatus according to the present disclosure, the light source may be glasses with a light source (e.g., referring to Figure 2 ) or a glasses frame with a light source, a desktop light source, a light source mounted on a mobile terminal, or a light source mounted near or in front of the face. According to some embodiments, since specific light can be irradiated from a light source mounted near or in front of the face (such as glasses with a light source or a glasses frame with a light source, which can be easily worn and without discomfort in daily use), they are highly practical and can irradiate light at any time even in various situations and different environments.

[0165] In the method and device according to the present disclosure, the light source can be a non-installed light source such as a portable light source, or an installed light source such as indoor lighting, a table stand, and a dedicated device. According to some embodiments, it can be made into a device in the form of various light sources suitable for the use environment. For example, the light source can be used in combination with glass, eyeglass lenses, or contact lenses that allow ultraviolet light to pass through. In addition, sunlight that passes through glass, eyeglass lenses, or contact lenses that allow ultraviolet light to pass through can also be used as a light source.

[0166] The light stimulation method according to the present disclosure is a method for treating and / or preventing Parkinson's disease by irradiating a living organism (e.g., mammals including humans) with light of a specific wavelength continuously or at a specific flashing frequency, characterized in that the emission of light is controlled, which improves or inhibits at least one symptom selected from the group of motor symptoms and non-motor symptoms in the living organism receiving the light, or in other words, improves or inhibits cognitive memory disorders, working memory disorders, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating.

[0167] The device according to the present disclosure is a device for treating and / or preventing Parkinson's disease by continuously irradiating a biological body with ultraviolet light, and is characterized by comprising a light source for emitting ultraviolet light and an emission time controller for irradiating the ultraviolet light for a specific time or a specific period of time.

[0168] In addition, as described below in conjunction with the accompanying drawings, in some embodiments of the present disclosure, the following are provided: a method for treating and / or preventing Parkinson's disease in a subject in need of treatment and / or prevention; a method for treating and / or preventing at least one symptom selected from the following symptom group in a subject in need of treatment and / or prevention: motor symptoms and non-motor symptoms, or in other words, cognitive memory impairment, working memory impairment, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, Light, parosmia, fatigue and sweating; a device for treating and / or preventing Parkinson's disease by light stimulation; a device for treating and / or preventing at least one symptom selected from the following symptom group by light stimulation: motor symptoms and non-motor symptoms, or in other words, cognitive memory disorders, working memory disorders, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, parosmia, fatigue and sweating; a method for operating the device; and a computer program for executing the operating method. BRIEF DESCRIPTION OF THE DRAWINGS

[0169] Figure 1 It is a schematic diagram of the parts of the brain;

[0170] Figure 2 is an example of violet glasses that shine violet light;

[0171] Figure 3is a graph showing the relationship between the wavelength and the spectral irradiance of a violet fluorescent lamp;

[0172] Figure 4 is the spectrum of an LED with a peak wavelength of 375nm;

[0173] Figure 5 is a block diagram of an embodiment of an apparatus for controlling biological functions according to the present invention;

[0174] Figure 6 is a micrograph showing that VL inhibits the formation of aggregates containing α-synuclein; and

[0175] Figure 7 are micrographs showing that VL inhibits the formation of aggregates containing p62. DETAILED DESCRIPTION

[0176] A method for treating and / or preventing Parkinson's disease in a subject in need of treatment and / or prevention; a method for treating and / or preventing at least one symptom selected from the following symptom group in a subject in need of treatment and / or prevention: motor symptoms and non-motor symptoms, or in other words, cognitive memory impairment, working memory impairment, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating ; A device for treating and / or preventing Parkinson's disease by light stimulation; A device for treating and / or preventing at least one symptom selected from the following symptom group: cognitive memory disorder, working memory disorder, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, parosmia, fatigue and sweating; A method for operating the device; and a computer program for executing the operating method, which will be described in conjunction with the accompanying drawings. The present invention is not limited to the following embodiments and examples, and includes various modifications and application examples within the scope of the present invention.

[0177] [Method for treating and / or preventing Parkinson's disease]

[0178] The method for treating and / or preventing Parkinson's disease according to the present disclosure comprises irradiating light of a specific wavelength to a subject in need of treatment and / or prevention.

[0179] The inventors of the present invention have found that by irradiating a subject with light of a specific wavelength, symptoms of Parkinson's disease, such as visual hallucinations, can be improved. Therefore, one aspect of the present disclosure relates to a method for treating and / or preventing Parkinson's disease in a subject in need of treatment and / or prevention, and the method includes improving at least one symptom selected from the following symptom group by irradiating the subject with light of a specific wavelength: motor symptoms and non-motor symptoms, or in other words, cognitive memory disorders, working memory disorders, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating. Here, the subject can be a human with Parkinson's disease or a human at risk of developing Parkinson's disease.

[0180] As symptoms of Parkinson's disease, examples of motor symptoms include resting tremor, akinesia, muscle rigidity and postural reflex disorders, and examples of non-motor symptoms include autonomic symptoms, cognitive impairment, olfactory disorders, sleep disorders, psychological symptoms (such as depression and anxiety, visual hallucinations or illusions, delusions, etc.), fatigue, pain and weight loss.

[0181] In the diagnosis of Parkinson's disease, first check whether there are any motor symptoms, and then check whether there are symptoms supporting Parkinson's disease and symptoms supporting diseases other than Parkinson's disease to determine whether it is Parkinson's disease or a disease other than Parkinson's disease.

[0182] According to the Hoehn & Yahr severity classification, patients with Parkinson's disease can be divided into Grade I, Grade II, Grade III, Grade IV and Grade V (Grade I: tremor and muscle rigidity of the hands and legs are observed only on one side of the body. There is no physical function impairment or slight impairment (if any); Grade II: tremor of both hands and legs and bilateral muscle rigidity are observed; Grade III: short steps and freezing of gait (FOG) are observed when walking; Grade IV: getting up and walking become difficult; Grade V: need to use a wheelchair). In addition, for the evaluation of Parkinson's disease, UPDRS (Unified Parkinson's Disease Rating Scale) can be used. UPDRS is a unified assessment standard for Parkinson's disease (PD) published in 1987, which contains a total of 42 assessment items, divided into four parts (Part I: Mental, behavioral and emotional; Part II: Activities of daily living (ADL); Part III: Motor function; Part IV: Treatment complications). In the context of the present disclosure, the therapeutic effect of Parkinson's disease can be judged based on these standards. The effectiveness of Parkinson's disease treatment can be evaluated based on the PDQ-39, a disease-specific QoL (quality of life) standard. The PDQ-39 consists of 39 questions in 8 domains, and the higher the value, the lower the QoL.

[0183] As described above, one aspect of the present disclosure relates to a method for treating and / or preventing Parkinson's disease in a subject in need of treatment and / or prevention, the method comprising irradiating the subject with light of a specific wavelength. In addition, the method may include treating and / or preventing Parkinson's disease in a subject by irradiating the subject with light of a specific wavelength to improve or prevent at least one symptom selected from motor symptoms and non-motor symptoms in the subject, or in other words, cognitive memory impairment, working memory impairment, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations, and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue, and sweating.

[0184] At this stage, supportive measures to relieve symptoms are the main focus of Parkinson's disease treatment. The basis of treatment is drug therapy, and as drugs, agents such as dopamine precursors (levodopa; L-dopa) and dopamine agonists (such as bromocriptine mesylate, pergolide mesylate, cabergoline, talipexol hydrochloride, pramipexole hydrochloride, ropinirole hydrochloride, rotigotine, and apomorphine hydrochloride hydrate), anticholinergic agents (such as trihexyphenidyl hydrochloride and biperiden), monoamine oxidase B inhibitors (such as selegiline, safinamide, and rasagiline), COMT inhibitors (such as entacapone and opicapone), norepinephrine precursors (such as droxidopa), adenosine A2A antagonists (such as istradefylline), antipsychotic agents (such as quetiapine and amantadine), zonisamide, and amantadine are used. Therefore, the treatment and / or prevention methods according to the present disclosure can be applied to patients who are being or have been administered these agents. The treatment and / or prevention methods according to the present disclosure can be used in combination with the administration of these agents.

[0185] For example, the MMSE (Mini-Mental State Examination) can be used to assess cognitive memory impairment and working memory impairment. The MMSE consists of 11 questions, and the subject answers each of these questions asked by the questioner one by one. The time limit for each question is 10 seconds, and the next question will be asked after the time limit. The maximum score of this test is 30 points. Scores of 23 points and below may be judged as "suspected dementia", and scores in the range of 24 to 27 points may be judged as "suspected mild cognitive impairment (MCI)". In addition, the revised Hasegawa Dementia Scale–Revised (HDS-R) can be used instead of MMSE or as a supplement to MMSE. HDS-R consists of 9 questions and focuses more on memory than MMSE.

[0186] From the research at the molecular level, it is clear that the deposition of alpha-synuclein and p62 proteins is observed in the brains of patients with Parkinson's disease. The inventors of the present invention have found that the deposition of alpha-synuclein and p62 proteins in the brain can be inhibited by irradiating a subject with light of a specific wavelength. Therefore, one aspect of the present disclosure relates to a method of inhibiting or improving the deposition of alpha-synuclein and p62 proteins in the brains of patients with Parkinson's disease, the method comprising irradiating a subject with light of a specific wavelength.

[0187] From studies at the cellular level, it is clear that the number of oligodendrocytes and differentiated myelin, which are glial cells, is reduced in Parkinson's disease. The inventors of the present invention have found that the proliferation and / or differentiation of oligodendrocytes can be accelerated by irradiating a subject with light of a specific wavelength. Therefore, one aspect of the present disclosure relates to a method for accelerating the proliferation and / or differentiation of oligodendrocytes in a patient with Parkinson's disease who needs treatment and / or prevention, which comprises irradiating the patient with light of a specific wavelength.

[0188] In some embodiments of the method according to the present disclosure, the light used may be purple light. In addition, in some embodiments, the specific wavelength used includes a wavelength in the range of 360nm to 400nm, and in particular may include a wavelength of about 380nm. The flicker frequency may be, for example, 0Hz or a frequency in the range of 30Hz to 70Hz, in particular 0Hz or a frequency in the range of 35Hz to 60Hz. Specifically, the flicker frequency may be 0Hz or about 40Hz. The irradiation conditions may also include the irradiation time of the light source. The light source may be glasses with a light source or a glasses frame with a light source, a desktop light source, such as a bedside table lamp, desk lighting, a light source installed on a mobile terminal, a light source installed near or in front of the face, a portable light source, indoor lighting, a wall-mounted lamp, a ceiling lamp, a table lamp, but not limited to these light sources.

[0189] In some embodiments of the present disclosure, the specific time of irradiation light is, for example, 10 seconds or more, 20 seconds or more, 30 seconds or more, 40 seconds or more, 50 seconds or more, 1 minute or more, 3 minutes or more, 5 minutes or more, 10 minutes or more, 15 minutes or more, 30 minutes or more, 1 hour or more, 2 hours or more, 3 hours or more, 4 hours or more, 5 hours or more, 10 hours or more, 20 hours or more, 30 hours or more, 40 hours or more, 50 hours or more, 100 hours or more, 150 hours or more, 200 hours or more, 250 hours or more, or 300 hours or more, as the total time of irradiation light. In addition, the specific time of irradiation light is, for example, 100000 hours or less, 10000 hours or less, 1000 hours or less, 500 hours or less, 300 hours or less or 100 hours or less. The specific time of irradiation light, such as the time of continuous irradiation, is 10 seconds or more, 20 seconds or more, 30 seconds or more, 40 seconds or more, 50 seconds or more, 1 minute or more, 3 minutes or more, 5 minutes or more, 10 minutes or more, 15 minutes or more, 30 minutes or more, 1 hour or more, 2 hours or more, 3 hours or more, 4 hours or more, 5 hours or more, 10 hours or more, or 20 hours or more. In addition, the specific time of irradiation light, such as the time of continuous irradiation, is 20 hours or less, 10 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, 30 minutes or less, 15 minutes or less, 10 minutes or less, 5 minutes or less, 3 minutes or less, 1 minute or less, 50 seconds or less, 40 seconds or less, 30 seconds or less, or 20 seconds or less. In addition, the specific time of irradiation light can be any time within the range of 10 seconds to 24 hours per day, such as 10 seconds, 30 seconds, 45 seconds, 1 minute, 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 18 hours and 24 hours, or it can be any time included in the range specified by the above arbitrary time (for example, the range of 1 hour to 12 hours). The specific cycle of continuous irradiation light can be the following cycle: one day or longer, two days or longer, three days or longer, four days or longer, five days or longer, six days or longer, one week or longer, two weeks or longer, three weeks or longer, one month or longer, two months or longer, three months or longer, six months or longer, one year or longer, two years or longer, three years or longer, or a cycle longer than these cycles.The specific period of continuous light exposure can be, for example, ten years or less, five years or less, one year or less, six months or less, three months or less, two months or less, one month or less, three weeks or less, two weeks or less, one week or less, six days or less, five days or less, four days or less, three days or less or two days or less.

[0190] One aspect of the present disclosure relates to a method for treating and / or preventing Parkinson's disease in a subject in need of treatment or prevention, by controlling a light irradiation device to irradiate light of a specific wavelength to the subject, thereby improving or inhibiting at least one symptom selected from the following symptom group: cognitive memory impairment, working memory impairment, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, parosmia, fatigue and sweating. In some embodiments, the light irradiation device is capable of irradiating purple light. In addition, in some embodiments, the light irradiation device is capable of irradiating light with a wavelength in the range of 360nm to 400nm, in particular, light with a wavelength of about 380nm. The light irradiation device can control the flickering frequency to be 0Hz or a frequency in the range of 30Hz to 70Hz, in particular 0Hz or a frequency in the range of 35Hz to 60Hz, and the flickering frequency can be particularly controlled to be 0Hz or about 40Hz. The light irradiation device may be a device capable of controlling the irradiation time. The light source may be in the form of glasses with a light source or a glasses frame with a light source, a desktop light source, a light source installed in a mobile terminal, a light source installed near or in front of the face, a portable light source, indoor lighting, and a desk lamp, but is not limited thereto.

[0191] [Device]

[0192] One aspect of the present disclosure relates to a device for treating and / or preventing Parkinson's disease by light stimulation. In some embodiments, the device for treating and / or preventing Parkinson's disease according to the present disclosure may include at least one light source that emits light and a driving circuit that drives the light source. Here, the light emitted by the light source is light of a specific wavelength, which, when irradiated onto a biological body, produces an effect of treating and / or preventing Parkinson's disease.

[0193] In addition, one aspect of the present disclosure relates to a device for treating and / or preventing diseases by light stimulation, which is treated and / or prevented by dopamine precursors (levodopa; L-dopa) and dopamine agonists (such as bromocriptine mesylate, pergolide mesylate, cabergoline, talipexol hydrochloride, pramipexole hydrochloride, ropinirole hydrochloride, rotigotine and apomorphine hydrochloride hydrate), anticholinergic agents (such as benhexyphenidyl hydrochloride and biperiden), monoamine oxidase B inhibitors (MAOB inhibitors) (selegiline, safinamide and rasagiline), COMT inhibitors (such as entacapone and opicapone), norepinephrine precursors (droxidopa), adenosine A2A receptor antagonists (such as istradefylline), zonisamide, amantadine and antipsychotic agents (such as quetiapine). In some embodiments, the device for treating and / or preventing at least one symptom selected from the group consisting of cognitive memory disorder, working memory disorder, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, parosmia, fatigue and sweating according to the present disclosure may include at least one light source emitting light and a driving circuit for driving the light source. Here, when the light emitted by the light source is irradiated onto the organism, it produces an effect of accelerating the improvement or inhibiting at least one symptom selected from the following symptom group: cognitive memory disorder, working memory disorder, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, parosmia, fatigue and sweating.

[0194] In the present specification, a device for treating and / or preventing Parkinson's disease by light stimulation is a device for treating and / or preventing at least one symptom selected from the following symptom group, sometimes collectively referred to as "device for controlling biological functions" or simply as "device": cognitive memory impairment, working memory impairment, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating.

[0195] These devices are believed to be able to stimulate the central nervous system of an organism by controlling the irradiation state of light. As described above, at least one symptom selected from the group consisting of cognitive memory impairment, working memory impairment, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal sense of smell, fatigue and sweating in patients subjected to light stimulation is improved or suppressed, thereby leading to the treatment and / or prevention of Parkinson's disease.

[0196] In some embodiments, as described above, the device according to the present disclosure is a device for treating and / or preventing Parkinson's disease, which accelerates the improvement or inhibition of at least one symptom selected from the following symptom group by irradiating purple light to the organism continuously or at a specific flashing frequency: cognitive memory disorder, working memory disorder, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating. The device is characterized in that it includes a light source that emits purple light, a light emission cycle controller that controls the purple light to be irradiated continuously or at a specific flashing frequency, and a light emission time controller that allows the purple light to be irradiated for a specific time or a specific time period, and is a device for treating and / or preventing a disease.

[0197] In addition, in some embodiments, the device according to the present disclosure is a device for controlling biological functions related to Parkinson's disease by continuously irradiating ultraviolet light to a biological body, characterized in that it includes a light source that emits ultraviolet light and a light emission time controller that allows the ultraviolet light to be irradiated for a specific time or a specific time period.

[0198] In addition, in some embodiments, the device according to the present disclosure relates to a device for treating and / or preventing the above-mentioned diseases by light stimulation, which includes at least one light source emitting light and a driving circuit for driving the light source, and the light emitted by the light source is a light of a specific wavelength that produces an effect when irradiated on a biological body. Therefore, one aspect of the present disclosure relates to a device for treating and / or preventing Parkinson's disease by light stimulation, which is configured to include at least one light source emitting light and a driving circuit for driving the light source, and the driving circuit includes at least one processor that is communicatively connected to the light source and at least one memory, and at least one memory for storing commands executable by the processor, the light source emits light of a specific wavelength that produces an effect of treating and / or preventing Parkinson's disease when irradiated on a biological body. In addition, one aspect of the present disclosure relates to a device for treating and / or preventing at least one symptom selected from the following symptom group by light stimulation: cognitive memory disorder, working memory disorder, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating, the device is configured to include at least one light source emitting light and a driving circuit driving the light source, the driving circuit including at least one A processor communicatively connected to a light source and at least one memory, and at least one memory for storing commands executable by the processor, the light source emitting light of a specific wavelength, which is irradiated onto a biological body to produce treatment and / or inhibition of at least one symptom selected from the following symptom group: cognitive memory impairment, working memory impairment, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal sense of smell, fatigue and sweating.

[0199] (light source)

[0200] The wavelength of the light emitted by the light source is not particularly limited. In some embodiments, violet light defined by a wavelength range of 360 nm to 400 nm is used.

[0201] Preferably, a light source with an oscillation frequency in the range of 0 Hz (continuous irradiation light, direct light) to 150 Hz can be used. This frequency can be adjusted in units of 0.5 Hz and 1 Hz by the setting of the controller, and light with any flickering frequency can be generated. As the flickering frequency increases, the advantage is that the flickering is no longer perceived, although this perception varies from person to person. The flickering frequency is not limited to the 40 Hz used in the experimental example.

[0202] The irradiance of the light source can be variable or constant. Although in some embodiments a maximum output of 310 μW / cm 2 The light source can be configured to have an irradiance of, for example, 0.1 μW / cm 2 (0.001W / m 2 ) to 5000μW / cm 2 (50W / m2), or for example, irradiance of 1μW / cm 2 (0.01W / m 2 ) to 1000μW / cm 2 (10W / m 2 ), or for example, the irradiance is within the range of 0.5 μW / cm 2 (0.005W / m 2 ) to 500μW / cm 2 (5W / m 2 ) or the irradiance is within 0.5μW / cm 2 Up to 1000μW / cm 2 In the range of 5 μW / cm2 to 1000 μW / cm 2 In the range of 10 μW / cm 2 Up to 1000μW / cm 2 In the range of 100 μW / cm 2 Up to 500μW / cm 2 In the range of 200μW / cm 2 Up to 400μW / cm 2 In addition, examples of the irradiance of the light source include: the irradiance intensity of the light incident on the eye is, for example, within the range of 0.1 μW / cm 2 (0.001W / m 2 ) to 5000μW / cm 2 (50W / m 2 ) range, or for example, within 1 μW / cm 2 (0.01W / m 2 ) to 1000μW / cm 2 (10W / m 2 ) range, or for example, within 0.5 μW / cm 2 (0.005W / m 2 ) to 500μW / cm 2 (5W / m 2 ) or within 0.5μW / cm 2 Up to 1000μW / cm 2 range, or for example, within 5 μW / cm2 Up to 1000μW / cm 2 range, or for example, within 10 μW / cm 2 Up to 1000μW / cm 2 range, or for example, 100 μW / cm 2 Up to 500μW / cm 2 range, or for example, 200 μW / cm 2 Up to 400μW / cm 2 range. In addition, since a light source with this irradiance can be easily used in glasses or eyeglass frames and other portable irradiation devices, it can be worn even in daily life. In particular, even with a very small amount of weak light (light with weak optical intensity), the occurrence of its characteristic phenomena has been verified, and its effects on various parts of the organism including the brain, as well as its application in cell activities (including use in the sense of gene expression control) can be expected.

[0203] Light can be specified based on relative brightness. Since the characteristics of the present invention can be achieved even with a low relative brightness, purple light that produces a stimulating effect in the organism can be irradiated while flashing at a low relative brightness, and a desired part can be stimulated without burdening the organism.

[0204] Preferably, the irradiation time is arbitrarily set according to the purpose of light irradiation, which can be a short time or a long time. The light can be irradiated intermittently (at fixed intervals or irregular intervals) or continuously. The irradiation time of light can be set to a time period between 8 am and 1 pm, between 9 am and 12 noon, between 10 am and 11 am, and the time period can be set to at least 10 minutes, at least 15 minutes, at least 20 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours or at least 5 hours. In some embodiments, the irradiation of a 3-hour period from 9 am to 12 noon, or the irradiation of a 2-hour period from 9 am to 11 am is used. In the case of setting the irradiation time in this way, a timing function can be used.

[0205] The light source may be glasses or glasses frames with a light source. Such glasses or glasses frames are easy to wear, and their light sources emit light at a flashing frequency suitable for the glasses or glasses frames, which does not cause discomfort when worn every day, so they are highly practical and can be worn at any time in various situations and different environments. In addition, the light source may also be a desktop light source, or a light source installed near or in front of the face (such as a light source installed in a mobile terminal) or a non-installed light source (such as a portable light source), or it may be an installed light source (such as indoor lighting, table lamps, and special equipment), and may be a device of various light source forms suitable for the use environment.

[0206] (Controller)

[0207] The controller is a part that controls the irradiation condition of the light from the light source (continuous irradiation or irradiation at a flashing frequency). The controller may be provided with a power source for supplying power to the light source, and such a power source may be a battery, or a wire may be connected to a battery installed at a different location. In the case of being fixed at a certain location, it may be connected to a household power source.

[0208] Preferably, the controller changes the light irradiation conditions, such as flickering frequency, irradiance, irradiation time, irradiation start time, and irradiation end time, by transmitting and receiving with an independent controller such as a portable terminal. Since the controller independently controls the above-mentioned various irradiation conditions, the desired effect can be achieved by arbitrarily setting the irradiation conditions suitable for controlling the desired biological function.

[0209] In addition, the controller may have control functions and timing functions of the light source. Examples of control functions include functions such as changing the frequency and irradiance and setting the irradiation time. And, examples of timing functions include the ability to set the irradiation time. These control functions and timing functions may be provided integrally with the instrument or as separate components.

[0210] As one embodiment of the device according to the present disclosure, Figure 5 A block diagram of a simplified example of an apparatus that can be used to control the above-mentioned biological functions is shown in FIG. Figure 5 The device shown in may include various functions of a device for treating and / or preventing Parkinson's disease by light stimulation as described in this specification and a device for treating and / or preventing at least one symptom selected from the following symptom group by light stimulation (these devices may be collectively referred to as "devices for controlling biological functions"): cognitive memory disorders, working memory disorders, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating. Therefore, all the devices mentioned above in this specification can be used Figure 5 The device for controlling biological functions may include a light source 10 and a controller 20. The light source 10 irradiates light of a specific wavelength. Preferably, the wavelength of the light irradiated by the light source 10 includes the aforementioned VL (violet light) or a wavelength range of 360nm to 400nm, and more preferably includes a wavelength of 380nm. The light source 10 may be any light source, and from the perspectives of small size, long life, and easy flicker control, it is preferred to use a light emitting diode (LED) (for an example of a violet light fluorescence spectrum, refer to Figure 3 , LED spectrum example reference Figure 4The number of the light sources 10 can be one or more according to factors such as the expected illumination intensity of the light source and the expected illumination range of the light source.

[0211] The controller 20 is connected to the light source 10 via a wired connection or a wireless connection, and is configured to control the irradiation conditions of the light source 10. The irradiation conditions may include at least one of the flickering frequency and the irradiation time of the light source 10, and therefore, the controller 20 may include at least one of a flickering frequency controller 20a and an irradiation time controller 20b. The flickering frequency may preferably be 0 Hz or a frequency in the range of 30 Hz to 75 Hz, more preferably 0 Hz or a frequency in the range of 35 Hz to 45 Hz, even more preferably 0 Hz or specifically 40 Hz. A flickering frequency of 0 Hz indicates continuous irradiation of light. The irradiation time may be arbitrarily set to a range of, for example, 10 seconds to 24 hours per day, and the specific time for the irradiation to continue may be arbitrarily set, such as a period of one day to several years, or longer.

[0212] The controller 20 may include a processor such as a CPU (central processing unit) and perform processing for controlling the illumination conditions of the light source 10. The processing performed by the controller 20 may be implemented by a computer program, or may be implemented in hardware by a logic circuit. The computer program may be stored in a computer-readable recording medium. The recording medium having the computer program recorded thereon may be a non-temporary recording medium. The non-temporary recording medium is not particularly limited and may be a recording medium such as a memory card and a CD-ROM (Compact Disc–Read Only Memory). The computer program stored in the recording medium may be installed in the computer unit via a suitable reader. In the case where the recording medium is a memory card, examples of suitable readers include a card reader; in the case where the recording medium is a CD-ROM, a suitable reader is, for example, a CD (optical disc) drive. In addition, the computer program may be a computer program downloaded to the computer unit from an external server via a communication network.

[0213] In the device according to the present disclosure, the driving circuit may include at least one processor communicatively connected to the light source and at least one memory, and at least one memory for storing commands executable by the processor.

[0214] exist Figure 5The light source 10 in the device for controlling biological functions shown can be glasses with a light source or a glasses frame with a light source, a desktop light source, a light source installed in a mobile terminal, a light source installed near or in front of the face, a portable light source, indoor lighting or a table lamp. In addition, the device for controlling biological functions can be provided as a product with a light source, which has at least the light source 10 installed between the light source 10 and the controller 20, including glasses or glasses frames, desktop lamps, mobile terminals, mobile terminal housings, head-mounted items (such as hats, headphones), portable lamps, indoor lighting or table lamps.

[0215] As described above, the device for controlling biological functions through light stimulation disclosed in the present invention can achieve the treatment and / or prevention of Parkinson's disease, as well as the treatment and / or prevention of at least one symptom selected from the following symptom group: cognitive memory disorders, working memory disorders, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating.

[0216] In addition, one aspect of the present invention relates to a method for operating a device for controlling a biological function by light stimulation. Therefore, some embodiments of the present disclosure relate to a method for operating the device, which is used to control the above-mentioned biological function, or in other words, for treating and / or preventing Parkinson's disease, and treating and / or preventing at least one symptom selected from the following symptom group: cognitive memory disorder, working memory disorder, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal smell, fatigue and sweating, the device includes a light source that irradiates a specific wavelength of light to a biological body continuously or at a specific flickering frequency, and a controller that controls the flickering frequency of the light source, and the device irradiates a specific wavelength of light to a biological body continuously or at a specific flickering frequency. Here, the flickering frequency of the light source can be controlled to be 0 Hz or a frequency in the range of 30 Hz to 75 Hz. In addition, the light source can be a light source that irradiates a wavelength of light in the range of 360 nm to 400 nm to the biological body. In addition, one aspect of the present invention relates to a computer program that causes an apparatus including a light source and a controller to execute the above-mentioned operation method, wherein the light source irradiates light of a specific frequency to a biological body continuously or at a specific flickering frequency, and the controller controls the flickering frequency of the light source.

[0217] The computer program according to the present disclosure may store commands in a non-transitory computer-readable medium. When the processor executes the command, the computer program according to the present disclosure can execute predetermined steps. Therefore, one aspect of the present disclosure also relates to a computer-readable medium, which is a non-transitory computer-readable medium having commands stored therein, and when the commands are executed by the processor, it can perform the following steps on a device (which includes a light source that irradiates a specific wavelength of light to a biological body continuously or at a specific flickering frequency and a controller that controls the flickering frequency of the light source): a step of operating the device to control the flickering frequency of the light source to be 0 Hz or a frequency in the range of 30 Hz to 75 Hz through the controller; and a step of operating the device so that the light source irradiates light with a wavelength of 360 nm to 400 nm to the biological body.

[0218] In addition, one aspect of the present invention relates to an apparatus for treating and / or preventing Parkinson's disease by light stimulation, which may include glass, eyeglass lenses or contact lenses that allow violet light to pass through. By using such an apparatus, a beneficial effect can be exerted on the organism, such as improving or inhibiting at least one symptom selected from the following symptom group: cognitive memory impairment, working memory impairment, irritability, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), impulse control disorders, orthostatic hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain, weight loss, abnormal sense of smell, fatigue and sweating. By using such an apparatus, it is possible to achieve the treatment and / or prevention of Parkinson's disease.

[0219] Example

[0220] Example 1. Inhibition of α-synuclein deposition by VL irradiation

[0221] One week before administration of α-synuclein to the mouse brain, VL irradiation (40 Hz; irradiation intensity of light incident on the eye was 310 μW / cm 2 ) for three hours. In addition, after the administration of α-synuclein, VL was irradiated every day (the irradiation intensity of the light incident on the eye was 310 μW / cm 2 ) for three hours, and samples were taken two weeks to six months after irradiation. The results showed that the formation of aggregates in the striatum (detected by anti-phosphorylated synuclein (psyn)) was delayed by VL irradiation ( Figure 6 ). This result indicates the usability of violet light in Parkinson's disease, which is a neurodegenerative disease. In other words, this suggests that it is possible to treat and / or prevent Parkinson's disease by irradiating violet light.

[0222] Example 2. Inhibition of p62 protein deposition by VL irradiation

[0223] Parkinson's disease model mice (ATG7 KO mice; Japanese Unexamined Patent Application Publication No. 2018-068136) that form aggregates due to autophagy deficiency were irradiated with ultraviolet light (40 Hz; the irradiation intensity of the light incident on the eye was 310 μW / cm 2 ) for three hours, the inhibitory effect on aggregation was observed ( Figure 7 ). This result indicates the usability of violet light in Parkinson's disease, which is a neurodegenerative disease. In other words, this suggests that it is possible to treat and / or prevent Parkinson's disease by irradiating violet light.

[0224] Example 3. Clinical trial in patients with Parkinson's disease

[0225] The following clinical trials have demonstrated the therapeutic effects of ultraviolet light therapy on Parkinson's disease (human) patients.

[0226] In a single-group study of 20 Parkinson's disease patients with progressive visual hallucinations, the subjects wore a violet light (with an incident light intensity of 310 μW / cm 2 , flashing at 40 Hz) goggles for three hours for 12 weeks. The study physician assessed safety by evaluating ophthalmological examinations, adverse events, and the occurrence of problems, and obtained other assessment scales, pareidolia test, MoCA-J, MDS-UPDRS parts I to IV (Movement Disorder Society–Unified Parkinson's Disease Rating Scale part III), MMSE (Mini Mental State Examination), PDQ (Parkinson's Disease Questionnaire)-39, PDSS-2 (Parkinson's Disease Sleep Scale-2), Cognitive Fluctuations Checklist, NPI-Q (Neuropsychiatric Inventory Questionnaire).

[0227] Through the above examinations, it was possible to determine whether there was an improvement effect on cognitive memory, working memory, caregiver QOL, sleep, hallucinations, visual hallucinations, and auditory hallucinations. In addition, as ophthalmological examinations, visual acuity, intraocular pressure, slit lamp microscopy, fundus examination, retinal tomography, and optical coherence tomography angiography were evaluated.

[0228] The treatment and / or prevention of Parkinson's disease by light stimulation is carried out according to an appropriate protocol based on the information provided in this specification.

[0229] Example 3-1 Case report of a patient with Parkinson's disease

[0230] A 71-year-old Parkinson's disease patient was exposed to 40Hz ultraviolet light for three hours a day during the day for 12 weeks (the intensity of the light incident on the eye was 310μW / cm 2 ), symptoms of sleep disorders and visual hallucinations were alleviated. In addition, after the violet light irradiation period ended, the symptoms of visual hallucinations and delirium were observed to recur. This suggests that Parkinson's disease can be treated and / or prevented by irradiating violet light.

[0231] Example 4. Clinical trial on patients with Parkinson's disease (2)

[0232] The therapeutic effect of ultraviolet light on human Parkinson's disease patients was demonstrated through the following clinical trials.

[0233] In a trial of a Parkinson's disease patient, the subject wore goggles with continuous violet light during the day (the intensity of the light incident on the eye was 310 μW / cm 2 ). The therapeutic effect on the subject was evaluated in a manner similar to that of Example 3.

[0234] All publications, applications, standards and patents mentioned in this specification are hereby incorporated by reference in their entirety; in the event of a conflict in terms, this specification shall prevail. The scope of the present invention is not limited by the specific embodiments described in this specification. In fact, in addition to the description in this specification, various modifications of the present invention will be obvious to those skilled in the art based on the above description and drawings. These modifications are intended to fall within the scope of the attached patent claims. Some or all of the embodiments may also be expressed as the following supplementary description, but the disclosure of this application is not limited to the following supplementary description.

Claims

1. A method for treating and / or preventing Parkinson's disease, comprising: A light irradiation device is used to irradiate light of a specific wavelength onto the subject.

2. The method according to claim 1, wherein: The method for treating and / or preventing Parkinson's disease is a method for treating and / or preventing motor symptoms and / or non-motor symptoms of Parkinson's disease.

3. The method according to claim 2, wherein: The motor symptom is at least one symptom selected from the following symptom group: difficulty speaking, drooling (excessive drooling), difficulty chewing, difficulty swallowing, difficulty eating movements, difficulty changing clothes, difficulty maintaining personal hygiene, difficulty writing, reduced hobbies and recreational activities, difficulty turning over, tremor, difficulty getting up from bed, chair and wheelchair, difficulty walking, loss of balance, freezing of gait (FOG), walking stiffness, speech difficulties, loss of facial expression, rigidity, finger tapping, hand movement disorders, hand pronation and supination movement disorders, toe tapping, lower limb agility disorders, postural stability disorders, difficulty maintaining posture, global spontaneity of movement (bradykinesia), hand postural tremor, hand kinesiology tremor, resting tremor amplitude, resting tremor and restless legs syndrome.

4. The method according to claim 2 or 3, wherein: The non-motor symptom is at least one symptom selected from the following symptom group: cognitive impairment, attention dysfunction, cognitive memory impairment, working memory impairment, depression, anxiety, sense of urgency, apathy, psychological symptoms (hallucinations, visual hallucinations, delusions and auditory hallucinations), dopamine disorder syndrome, impulse control disorder, orthostatic hypotension, postural hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain and other sensory abnormalities (smell abnormalities and visual abnormalities), weight changes, fatigue, sweating and syncope.

5. The method according to claim 4, wherein: At least one symptom selected from the following symptom group is caused by Parkinson's disease: cognitive impairment, attention dysfunction, cognitive memory impairment, working memory impairment, depressed mood, anxiety, urgency, apathy, psychological symptoms (hallucinations, visual hallucinations and auditory hallucinations), dopamine dysregulation syndrome, impulse control disorder, orthostatic hypotension, postural hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain and other sensory abnormalities (smell abnormalities and visual abnormalities), weight changes, fatigue, sweating and syncope.

6. The method according to any one of claims 1 to 5, wherein: The method for treating and / or preventing Parkinson's disease is a method for treating and / or preventing dyskinesia.

7. The method according to any one of claims 1 to 6, wherein: Parkinson's disease is characterized by being classified as one of Grade I, Grade II, Grade III, Grade IV, or Grade V according to the Hoehn & Yahr severity grade classification.

8. The method according to any one of claims 1 to 7, wherein: The light of the specific wavelength is irradiated to the subject continuously or at a specific flashing frequency.

9. The method according to any one of claims 1 to 8, wherein: The subject is currently taking or has taken at least one agent selected from the group consisting of levodopa, phenylalanine, tyrosine, bromocriptine mesylate, pergolide mesylate, cabergoline, talipexole hydrochloride, pramipexole hydrochloride, ropinirole hydrochloride, rotigotine, apomorphine hydrochloride hydrate, trihexyphenidyl hydrochloride, biperiden, selegiline, safinamide, rasagiline, entacapone, opicapone, droxidopa, istradefylline, quetiapine, zonisamide and amantadine.

10. The method according to any one of claims 1 to 9, wherein: The light is violet light.

11. The method according to any one of claims 1 to 10, wherein: The specific wavelength includes a wavelength within a range of 360 nm to 400 nm.

12. The method according to any one of claims 1 to 11, wherein: The specific wavelength includes a wavelength of about 380 nm.

13. The method according to any one of claims 1 to 12, wherein: The light is one of light that is continuously irradiated and light that flickers at a specific flickering frequency. The method of claim 13 , wherein the flickering frequency is in the range of 30 Hz to 70 Hz.

15. The method according to one of claims 13 and 14, wherein: The flickering frequency is in the range of 35 Hz to 60 Hz.

16. The method according to any one of claims 13 to 15, wherein: The flashing frequency is 40 Hz.

17. The method according to any one of claims 1 to 16, wherein: The light is irradiated during daytime.

18. The method according to any one of claims 1 to 17, wherein: The light was irradiated for 10 seconds or longer as the total time of light irradiation.

19. The method according to any one of claims 1 to 18, wherein the light is irradiated so that the irradiance of the light incident on the eye is between 0.5 μW / cm 2 Up to 1000μW / cm 2 within the range.

20. The method according to any one of claims 1 to 19, wherein: The light was irradiated for 5 minutes or more as the total time of light irradiation.

21. The method according to any one of claims 1 to 20, wherein: The light irradiation device is glasses with a light source or a glasses frame with a light source, a desktop light source, a light source installed in a mobile terminal, a light source installed near or in front of the face, a portable light source, indoor lighting and a desk lamp.

22. The method according to any one of claims 1 to 21, wherein: The subject is a human.

23. A device for treating and / or preventing Parkinson's disease by irradiating a subject with light of a specific wavelength continuously or at a specific flashing frequency, comprising: A light source that emits light of a specific wavelength, either continuously or at a specific flashing frequency.

24. The apparatus according to claim 23, further comprising: A controller controls emission of light, wherein the light induces, in the subject irradiated by the light, specific brain waves that are the same as, substantially the same as, or different from an irradiation state of the light.

25. The device according to claim 24, wherein: The controller performs control by changing irradiation conditions such as a flickering frequency of light of a specific wavelength, irradiance, irradiation time, irradiation start time, and irradiation end time by transmitting and receiving with a separate controller such as a portable terminal.

26. The apparatus according to claim 25, further comprising: A driving circuit drives the light source.

27. The device according to claim 26, wherein: The driving circuit includes at least one processor and at least one memory for storing commands executable by the processor, and The processor is communicatively connected to the light source and the memory.

28. The device according to any one of claims 23 to 27, wherein the device for treating and / or preventing Parkinson's disease treats and / or prevents motor symptoms and / or non-motor symptoms of Parkinson's disease.

29. The apparatus according to claim 28, wherein the motor symptom is at least one symptom selected from the group consisting of difficulty speaking, drooling (excessive drooling), difficulty chewing, difficulty swallowing, difficulty eating movements, difficulty changing clothes, difficulty maintaining personal hygiene, difficulty writing, reduced hobbies and recreational activities, difficulty turning over, tremor, difficulty getting up from a bed, chair and wheelchair, difficulty walking, loss of balance, freezing of gait (FOG), walking stiffness, speech difficulties, loss of facial expression, rigidity, finger tapping, hand movement disorders, hand pronation and supination movement disorders, toe tapping, lower limb agility disorders, postural stability disorders, difficulty maintaining posture, global spontaneity of movement (bradykinesia), hand postural tremor, hand kinetic tremor, resting tremor amplitude, resting tremor and restless legs syndrome.

30. The device according to one of claims 28 and 29, wherein The non-motor symptom is at least one symptom selected from the following symptom group: cognitive impairment, attention dysfunction, cognitive memory impairment, working memory impairment, depression, anxiety, sense of urgency, apathy, psychological symptoms (hallucinations, visual hallucinations, delusions and auditory hallucinations), dopamine disorder syndrome, impulse control disorder, orthostatic hypotension, postural hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain and other sensory abnormalities (smell abnormalities and visual abnormalities), weight changes, fatigue, sweating and syncope.

31. The device according to claim 30, wherein At least one symptom selected from the following symptom group is caused by Parkinson's disease: cognitive impairment, attention dysfunction, cognitive memory impairment, working memory impairment, depressed mood, anxiety, apathy, psychological symptoms (hallucinations, visual hallucinations, delusions and auditory hallucinations), dopamine dysregulation syndrome, impulse control disorder, orthostatic hypotension, postural hypotension, urinary system disorders, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorders, pain and other sensory abnormalities (smell abnormalities and visual abnormalities), weight changes, fatigue, sweating and syncope.

32. The device according to any one of claims 23 to 31, wherein the device for treating and / or preventing Parkinson's disease treats and / or prevents dyskinesia.

33. The device according to any one of claims 23 to 32, wherein: Parkinson's disease is classified into one of grades I, II, III, IV, and V according to the Hoehn & Yahr severity grade classification.

34. The device according to any one of claims 23 to 33, wherein the subject is being administered or has been administered at least one agent selected from the group consisting of: levodopa, phenylalanine, tyrosine, bromocriptine mesylate, pergolide mesylate, cabergoline, talipexole hydrochloride, pramipexole hydrochloride, ropinirole hydrochloride, rotigotine, apomorphine hydrochloride hydrate, trihexyphenidyl hydrochloride, biperiden, selegiline, safinamide, rasagiline, entacapone, opicapone, droxidopa, istradefylline, quetiapine, zonisamide and amantadine.

35. The device of any one of claims 23 to 34, wherein the light is violet light.

36. The device of any one of claims 23 to 35, wherein the specific wavelength comprises a wavelength within the range of 360 nm to 400 nm.

37. The device of any one of claims 23 to 36, wherein the specific wavelength comprises a wavelength of approximately 380 nm.

38. A device according to any one of claims 23 to 37, wherein the flickering frequency is in the range of 30 Hz to 70 Hz.

39. A device according to any one of claims 23 to 38, wherein the flickering frequency is in the range of 35 Hz to 60 Hz.

40. The device according to any one of claims 23 to 39, wherein: The flashing frequency is 40 Hz.

41. The device of any one of claims 23 to 40, wherein the light is irradiated during daytime.

42. The device according to any one of claims 23 to 41, wherein The light was irradiated for 10 seconds or longer as the total time of light irradiation.

43. The device according to any one of claims 23 to 42, wherein the light is irradiated so that the irradiance of the light incident on the eye is between 0.5 μW / cm 2 Up to 1000μW / cm 2 within the range.

44. The device according to any one of claims 23 to 43, wherein: The light was irradiated for 5 minutes or more as the total time of light irradiation.

45. The device according to any one of claims 23 to 44, wherein: The device is glasses with light sources or glasses frames with light sources, desktop light sources, light sources installed on mobile terminals, light sources installed near or in front of the face, portable light sources, indoor lighting and table lamps.

46. ​​The device according to any one of claims 23 to 45, wherein: Different wavelengths of light, sound, vibration, magnetic fields, and electric fields are applied along with irradiation with light of a specific wavelength.

47. A computer-readable medium, which is a non-transitory computer-readable medium storing commands and capable of causing the device according to any one of claims 23 to 46 to perform the following steps when a processor executes the commands, the device comprising a light source that irradiates a biological body with light of a specific wavelength continuously or at a specific flickering frequency, and a controller that controls the flickering frequency of the light source: The step of operating the device so that the controller controls the flickering frequency of the light source to 0 Hz or a frequency within a range of 30 Hz to 75 Hz; and A step of operating the device so that the light source irradiates light with a wavelength in the range of 360 nm to 400 nm toward the biological body.

48. An apparatus for treating and / or preventing Parkinson's disease by light stimulation, comprising: Glass, eyeglass lenses, or contact lenses that allow violet light to pass through.

Images